NCT05461027

Brief Summary

Percutaneous cryoablation is an alternative to urological surgery for T1a tumours, whose oncological efficacy decreases for the most central tumours due to a cold sink effect.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 12, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 15, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

December 27, 2024

Status Verified

December 1, 2024

Enrollment Period

1.7 years

First QC Date

July 12, 2022

Last Update Submit

December 24, 2024

Conditions

Kidney Cancer

Keywords

Kidney CancerCentral Kidney TumoursRenal Artery OcclusioncryoablationUrological surgeryT1a tumoursCold sink effectEndovascular balloon clampingRenal hilum

Outcome Measures

Primary Outcomes (1)

  • Description of the technique of percutaneous cryoablation of central renal tumours with temporary balloon obliteration of the renal artery

    Files analysed retrospectively from January 01, 2018 to December 31, 2021 will be examined

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult subject (≥18 years) who has undergone cryoablation of a central kidney tumour with temporary occlusion of the renal artery by an endovascular balloon at the HUS during the period 01/01/2018 to 30/12/2021

You may qualify if:

  • Adult subject (≥18 years)
  • Subject who has undergone cryoablation of a central kidney tumour with temporary occlusion of the renal artery by an endovascular balloon at the HUS during the period 01/01/2018 to 30/12/2021
  • Subject who has not expressed his/her opposition, after information, to the re-use of his/her data for the purpose of this research.

You may not qualify if:

  • Subject having expressed his/her opposition to participate in the study
  • Subject under legal protection, guardianship or curatorship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service d'Imagerie Interventionnelle - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Kidney Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Pierre-Alexis AUTRUSSEAU, MD

    Service d'Imagerie Interventionnelle - CHU de Strasbourg - France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2022

First Posted

July 15, 2022

Study Start

May 1, 2022

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

December 27, 2024

Record last verified: 2024-12

Locations

FR(1)